OA12883A - Lasofoxifene tablet and its coating. - Google Patents

Lasofoxifene tablet and its coating. Download PDF

Info

Publication number: OA12883A
Authority: OA; OAPI
Prior art keywords: phenyl; cellulose; sodium; tablet; active
Prior art date: 2002-07-10

Application number

OA1200500007A

Other languages

English (en)

Inventor

Daniel Scott Gierer

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-10

Filing date

2003-06-30

Publication date

2006-09-15

2003-06-30 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2006-09-15 Publication of OA12883A publication Critical patent/OA12883A/en

Links

GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 title claims abstract description 33
229960002367 lasofoxifene Drugs 0.000 title abstract description 30
238000000576 coating method Methods 0.000 title abstract description 10
239000011248 coating agent Substances 0.000 title abstract description 9
239000000203 mixture Substances 0.000 claims abstract description 99
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 61
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
235000012239 silicon dioxide Nutrition 0.000 claims abstract description 28
239000000377 silicon dioxide Substances 0.000 claims abstract description 27
150000001875 compounds Chemical class 0.000 claims description 33
239000003085 diluting agent Substances 0.000 claims description 27
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 21
239000008101 lactose Substances 0.000 claims description 20
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 19
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 19
239000007884 disintegrant Substances 0.000 claims description 19
239000000945 filler Substances 0.000 claims description 19
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 17
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 17
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
239000008108 microcrystalline cellulose Substances 0.000 claims description 17
229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
239000000651 prodrug Substances 0.000 claims description 17
229940002612 prodrug Drugs 0.000 claims description 17
229920002785 Croscarmellose sodium Polymers 0.000 claims description 15
229960001681 croscarmellose sodium Drugs 0.000 claims description 15
239000000314 lubricant Substances 0.000 claims description 14
-1 dextrates Chemical compound 0.000 claims description 11
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
239000002775 capsule Substances 0.000 claims description 8
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
239000000454 talc Substances 0.000 claims description 8
229910052623 talc Inorganic materials 0.000 claims description 8
229940033134 talc Drugs 0.000 claims description 8
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
239000001913 cellulose Substances 0.000 claims description 7
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
229920000609 methyl cellulose Polymers 0.000 claims description 7
235000010981 methylcellulose Nutrition 0.000 claims description 7
239000001923 methylcellulose Substances 0.000 claims description 7
229920001223 polyethylene glycol Polymers 0.000 claims description 7
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
229920002472 Starch Polymers 0.000 claims description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
239000008107 starch Substances 0.000 claims description 6
235000019698 starch Nutrition 0.000 claims description 6
239000002202 Polyethylene glycol Substances 0.000 claims description 5
239000003921 oil Substances 0.000 claims description 5
235000019198 oils Nutrition 0.000 claims description 5
235000019814 powdered cellulose Nutrition 0.000 claims description 5
229920003124 powdered cellulose Polymers 0.000 claims description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
229930195725 Mannitol Natural products 0.000 claims description 4
229920000881 Modified starch Polymers 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 4
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
239000011575 calcium Substances 0.000 claims description 4
229910052791 calcium Inorganic materials 0.000 claims description 4
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
235000010980 cellulose Nutrition 0.000 claims description 4
229920002678 cellulose Polymers 0.000 claims description 4
239000008121 dextrose Substances 0.000 claims description 4
239000000594 mannitol Substances 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
239000005720 sucrose Substances 0.000 claims description 4
229960000540 polacrilin potassium Drugs 0.000 claims description 3
WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 claims description 3
239000008109 sodium starch glycolate Substances 0.000 claims description 3
229920003109 sodium starch glycolate Polymers 0.000 claims description 3
229940079832 sodium starch glycolate Drugs 0.000 claims description 3
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
229920002261 Corn starch Polymers 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 claims description 2
229920002307 Dextran Polymers 0.000 claims description 2
239000004375 Dextrin Substances 0.000 claims description 2
229920001353 Dextrin Polymers 0.000 claims description 2
229920002774 Maltodextrin Polymers 0.000 claims description 2
239000005913 Maltodextrin Substances 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
235000021355 Stearic acid Nutrition 0.000 claims description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
229960003563 calcium carbonate Drugs 0.000 claims description 2
229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
235000010216 calcium carbonate Nutrition 0.000 claims description 2
229940095672 calcium sulfate Drugs 0.000 claims description 2
235000011132 calcium sulphate Nutrition 0.000 claims description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
239000008120 corn starch Substances 0.000 claims description 2
229940096516 dextrates Drugs 0.000 claims description 2
235000019425 dextrin Nutrition 0.000 claims description 2
235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
229960001031 glucose Drugs 0.000 claims description 2
229940075507 glyceryl monostearate Drugs 0.000 claims description 2
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 2
229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
229940035034 maltodextrin Drugs 0.000 claims description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
229920001983 poloxamer Polymers 0.000 claims description 2
235000010413 sodium alginate Nutrition 0.000 claims description 2
239000000661 sodium alginate Substances 0.000 claims description 2
229940005550 sodium alginate Drugs 0.000 claims description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
239000004299 sodium benzoate Substances 0.000 claims description 2
235000010234 sodium benzoate Nutrition 0.000 claims description 2
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
239000008117 stearic acid Substances 0.000 claims description 2
229960004274 stearic acid Drugs 0.000 claims description 2
235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
239000000811 xylitol Substances 0.000 claims description 2
235000010447 xylitol Nutrition 0.000 claims description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
229960002675 xylitol Drugs 0.000 claims description 2
239000011701 zinc Substances 0.000 claims description 2
229910052725 zinc Inorganic materials 0.000 claims description 2
229960005069 calcium Drugs 0.000 claims 2
229940032147 starch Drugs 0.000 claims 2
UMKXSOXZAXIOPJ-UHFFFAOYSA-N 5,6,7,8-tetrahydro-2-naphthol Chemical compound C1CCCC2=CC(O)=CC=C21 UMKXSOXZAXIOPJ-UHFFFAOYSA-N 0.000 claims 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
239000004698 Polyethylene Substances 0.000 claims 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
229960002086 dextran Drugs 0.000 claims 1
229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
229920000573 polyethylene Polymers 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
235000015424 sodium Nutrition 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 abstract description 23
238000004519 manufacturing process Methods 0.000 abstract description 16
239000001087 glyceryl triacetate Substances 0.000 abstract description 12
235000013773 glyceryl triacetate Nutrition 0.000 abstract description 12
229960002622 triacetin Drugs 0.000 abstract description 12
238000009513 drug distribution Methods 0.000 abstract description 2
239000004480 active ingredient Substances 0.000 abstract 2
238000000034 method Methods 0.000 description 31
239000003826 tablet Substances 0.000 description 30
239000002552 dosage form Substances 0.000 description 25
230000008569 process Effects 0.000 description 22
238000002156 mixing Methods 0.000 description 21
239000000243 solution Substances 0.000 description 18
229960001375 lactose Drugs 0.000 description 16
239000000546 pharmaceutical excipient Substances 0.000 description 13
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
238000009472 formulation Methods 0.000 description 12
229920000642 polymer Polymers 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000003086 colorant Substances 0.000 description 9
229940079593 drug Drugs 0.000 description 9
239000003814 drug Substances 0.000 description 9
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
238000005550 wet granulation Methods 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
239000000463 material Substances 0.000 description 7
239000002245 particle Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000009826 distribution Methods 0.000 description 6
238000007908 dry granulation Methods 0.000 description 6
229910052943 magnesium sulfate Inorganic materials 0.000 description 6
235000019341 magnesium sulphate Nutrition 0.000 description 6
239000003605 opacifier Substances 0.000 description 6
239000004014 plasticizer Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
238000005469 granulation Methods 0.000 description 5
230000003179 granulation Effects 0.000 description 5
239000010410 layer Substances 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 4
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
239000008186 active pharmaceutical agent Substances 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
229940088679 drug related substance Drugs 0.000 description 4
239000012535 impurity Substances 0.000 description 4
229960001021 lactose monohydrate Drugs 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000012044 organic layer Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000007916 tablet composition Substances 0.000 description 4
239000004408 titanium dioxide Substances 0.000 description 4
238000009827 uniform distribution Methods 0.000 description 4
INEHJXCWEVNEDZ-LUDNRVPPSA-N (2s,3s)-2,3-dihydroxybutanedioic acid;(5r,6s)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 INEHJXCWEVNEDZ-LUDNRVPPSA-N 0.000 description 3
HJOOGTROABIIIU-UHFFFAOYSA-N 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine;hydrochloride Chemical compound Cl.C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 HJOOGTROABIIIU-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000001680 brushing effect Effects 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
229950010500 lasofoxifene tartrate Drugs 0.000 description 3
229940095743 selective estrogen receptor modulator Drugs 0.000 description 3
239000000333 selective estrogen receptor modulator Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
PVPBHKCSQBLDEW-ZQOBQRRWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol 4-hydroxybutane-1-sulfonic acid Chemical compound OCCCCS(O)(=O)=O.OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O PVPBHKCSQBLDEW-ZQOBQRRWSA-N 0.000 description 2
LNXCMAIFYNBIAO-UHFFFAOYSA-N 1-[2-[4-(6-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine Chemical compound C=1CCC2=CC(OC)=CC=C2C=1C(C=C1)=CC=C1OCCN1CCCC1 LNXCMAIFYNBIAO-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
MNALUTYMBUBKNX-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21 MNALUTYMBUBKNX-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
239000005995 Aluminium silicate Substances 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
208000001132 Osteoporosis Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
208000025844 Prostatic disease Diseases 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
235000012211 aluminium silicate Nutrition 0.000 description 2
229960004977 anhydrous lactose Drugs 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
229910021485 fumed silica Inorganic materials 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
239000007887 hard shell capsule Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
229940073584 methylene chloride Drugs 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000003223 protective agent Substances 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000002904 solvent Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000004173 sunset yellow FCF Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
JWQYZECMEPOAPF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1=CC=C2CC(O)CCC2=C1 JWQYZECMEPOAPF-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
SRSIBTJGQWSANT-UHFFFAOYSA-N 1-[2-[4-(2-bromo-6-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine Chemical compound BrC=1CCC2=CC(OC)=CC=C2C=1C(C=C1)=CC=C1OCCN1CCCC1 SRSIBTJGQWSANT-UHFFFAOYSA-N 0.000 description 1
NAPIZYZVKMASNP-PXJZQJOASA-N 1-[2-[4-[(1r,2s)-6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenoxy]ethyl]pyrrolidine Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 NAPIZYZVKMASNP-PXJZQJOASA-N 0.000 description 1
NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 description 1
229920003084 Avicel® PH-102 Polymers 0.000 description 1
101150065749 Churc1 gene Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
YDWKSSWZGXRQET-UHFFFAOYSA-N Pyrrolidine, 1-[2-(4-bromophenoxy)ethyl]- Chemical compound C1=CC(Br)=CC=C1OCCN1CCCC1 YDWKSSWZGXRQET-UHFFFAOYSA-N 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
230000000274 adsorptive effect Effects 0.000 description 1
150000008051 alkyl sulfates Chemical class 0.000 description 1
235000012501 ammonium carbonate Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000012267 brine Substances 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
239000002834 estrogen receptor modulator Substances 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000005243 fluidization Methods 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
230000005484 gravity Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000007366 host health Effects 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
VDCLSGXZVUDARN-UHFFFAOYSA-N molecular bromine;pyridine;hydrobromide Chemical compound Br.BrBr.C1=CC=NC=C1 VDCLSGXZVUDARN-UHFFFAOYSA-N 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
150000002814 niacins Chemical class 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
238000009828 non-uniform distribution Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
150000002942 palmitic acid derivatives Chemical class 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
125000005547 pivalate group Chemical group 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000005498 polishing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
239000000565 sealant Substances 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
150000003377 silicon compounds Chemical class 0.000 description 1
239000005049 silicon tetrachloride Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960003010 sodium sulfate Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
150000003567 thiocyanates Chemical class 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
RIOQSEWOXXDEQQ-UHFFFAOYSA-O triphenylphosphanium Chemical compound C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-O 0.000 description 1
239000012808 vapor phase Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

OA1200500007A 2002-07-10 2003-06-30 Lasofoxifene tablet and its coating. OA12883A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US39509002P	2002-07-10	2002-07-10

Publications (1)

Publication Number	Publication Date
OA12883A true OA12883A (en)	2006-09-15

Family

ID=30115812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200500007A OA12883A (en)	2002-07-10	2003-06-30	Lasofoxifene tablet and its coating.

Country Status (35)

Country	Link
US (2)	US20040057992A1 (is)
EP (1)	EP1534248B1 (is)
JP (2)	JP4446446B2 (is)
KR (1)	KR100782693B1 (is)
CN (1)	CN100344278C (is)
AP (1)	AP2005003201A0 (is)
AR (1)	AR040434A1 (is)
AT (1)	ATE550017T1 (is)
AU (1)	AU2003247017B2 (is)
BR (1)	BR0312563A (is)
CA (1)	CA2489407C (is)
CY (1)	CY1112892T1 (is)
DK (1)	DK1534248T3 (is)
EA (1)	EA007268B1 (is)
EC (1)	ECSP055528A (is)
ES (1)	ES2395123T3 (is)
HN (1)	HN2003000206A (is)
HR (1)	HRP20041196A2 (is)
IL (2)	IL165746A0 (is)
IS (1)	IS7594A (is)
MA (1)	MA27318A1 (is)
MX (1)	MXPA05000394A (is)
NO (1)	NO20050018L (is)
NZ (1)	NZ537278A (is)
OA (1)	OA12883A (is)
PA (1)	PA8576201A1 (is)
PE (1)	PE20040104A1 (is)
PL (1)	PL374913A1 (is)
PT (1)	PT1534248E (is)
SI (1)	SI1534248T1 (is)
TN (1)	TNSN05006A1 (is)
TW (1)	TW200406222A (is)
UY (1)	UY27886A1 (is)
WO (1)	WO2004006895A1 (is)
ZA (1)	ZA200410196B (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8576201A1 (es) *	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US20040253305A1 (en) *	2003-06-12	2004-12-16	Luner Paul E.	Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) *	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
WO2006105806A1 (en) *	2005-04-07	2006-10-12	Miso Sabovic	Delaying the ageing process and disorders caused by ageing
CN101198319B (zh) *	2005-04-26	2012-08-01	大日本住友制药株式会社	含有双胍化合物的颗粒制剂
GB0516604D0 (en) *	2005-08-12	2005-09-21	Sandoz Ag	Rapidly dispersing/disintegrating compositions
CA2833706C (en)	2005-11-11	2014-10-21	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
PT3150586T (pt)	2007-02-23	2020-03-31	Gilead Sciences Inc	Moduladores de propriedades farmacocinéticas de agentes terapêuticos
CA2835910C (en) *	2007-04-25	2016-06-28	Warner Chilcott Company, Llc	Improved vitamin d content uniformity in pharmaceutical dosage forms
US20100055180A1 (en) *	2007-10-10	2010-03-04	Mallinckrodt Baker, Inc.	Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
WO2009048557A1 (en) *	2007-10-10	2009-04-16	Mallinckrodt Baker, Inc.	Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20090274757A1 (en) *	2008-05-01	2009-11-05	Wyeth	Pharmaceutical polish formulations
EA201591353A1 (ru)	2008-05-02	2016-01-29	Джилид Сайэнс, Инк.	Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
SI2451445T1 (sl) *	2009-07-06	2019-07-31	Boehringer Ingelheim International Gmbh	Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
WO2013059146A1 (en) *	2011-10-17	2013-04-25	Lexicon Pharmaceuticals, Inc.	Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
JP5818219B2 (ja)	2012-05-14	2015-11-18	塩野義製薬株式会社	６，７−不飽和−７−カルバモイルモルヒナン誘導体含有製剤
EP3043778B1 (en) *	2013-09-13	2017-09-06	Bayer Pharma Aktiengesellschaft	Pharmaceutical compositions containing refametinib
RU2539375C1 (ru) *	2013-11-07	2015-01-20	Общество С Ограниченной Ответственностью "Валента-Интеллект"	Фармацевтическая композиция в форме таблетки и способ ее получения
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103830196A (zh) *	2014-03-14	2014-06-04	王志刚	一种酒石酸拉索昔芬分散片及其制备方法
TWI535784B (zh)	2014-08-26	2016-06-01	財團法人工業技術研究院	剪切增稠配方、及包含其之複合材料
CN105434444B (zh) *	2014-09-29	2021-02-05	上海奥奇医药科技有限公司	一种A-失碳-5α雄甾烷化合物的口服制剂
MX382609B (es) *	2016-07-25	2025-03-13	Canopy Growth Corp	Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
CN110099680B (zh)	2016-10-11	2021-02-05	杜克大学	Er+乳腺癌的拉索昔芬治疗
CN117771239A (zh)	2018-04-10	2024-03-29	杜克大学	乳腺癌的拉索昔芬治疗
GB202116903D0 (en)	2021-11-18	2022-01-05	Sermonix Pharmaceuticals Inc	Lasofoxifene treatment of aromatase-resistant er+ cancer
CN114288258A (zh) *	2022-02-18	2022-04-08	山东新时代药业有限公司	一种单硝酸异山梨酯片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4182A (en) *		1845-09-09		Island
US4880636A (en) *	1988-05-13	1989-11-14	Franz Robert M	Film coated tablet of ranitidine HCl
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) *	1995-11-02	2002-12-16	Пфайзер Інк.	(-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW442286B (en) *	1996-02-28	2001-06-23	Pfizer	New therapeutic uses of estrogen agonists
US6372457B1 (en)	1997-01-14	2002-04-16	Arkion Life Sciences Llc	Process and materials for production of glucosamine
KR200161927Y1 (ko) *	1997-08-26	1999-12-01	윤종용	냉장고
YU26700A (sh) *	1999-05-24	2002-06-19	Pfizer Products Inc.	Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
US6436977B1 (en) *	1999-09-29	2002-08-20	Pfizer Inc.	Dosing regimens for lasofoxifene
US6419956B1 (en) *	1999-12-30	2002-07-16	Ancile Pharmaceuticals	Odor-masking coating for a pharmaceutical preparation
EP1145719A3 (en) *	2000-03-10	2001-11-14	Pfizer Products Inc.	Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations
AR029538A1 (es) *	2000-07-06	2003-07-02	Wyeth Corp	Composiciones farmaceuticas de agentes estrogenicos
AP2003002900A0 (en) *	2001-05-01	2003-12-31	Pfizer Prod Inc	Method for manufacturing a low dose pharmaceutical composition
PA8576201A1 (es) *	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco

2003
- 2003-06-23 PA PA20038576201A patent/PA8576201A1/es unknown
- 2003-06-30 ES ES03764059T patent/ES2395123T3/es not_active Expired - Lifetime
- 2003-06-30 DK DK03764059.6T patent/DK1534248T3/da active
- 2003-06-30 WO PCT/IB2003/003074 patent/WO2004006895A1/en not_active Ceased
- 2003-06-30 HR HR20041196A patent/HRP20041196A2/hr not_active Application Discontinuation
- 2003-06-30 CN CNB038162881A patent/CN100344278C/zh not_active Expired - Fee Related
- 2003-06-30 IL IL16574603A patent/IL165746A0/xx unknown
- 2003-06-30 EA EA200401583A patent/EA007268B1/ru not_active IP Right Cessation
- 2003-06-30 PL PL03374913A patent/PL374913A1/xx not_active Application Discontinuation
- 2003-06-30 JP JP2004521001A patent/JP4446446B2/ja not_active Expired - Fee Related
- 2003-06-30 AU AU2003247017A patent/AU2003247017B2/en not_active Ceased
- 2003-06-30 AP AP2005003201A patent/AP2005003201A0/xx unknown
- 2003-06-30 PT PT03764059T patent/PT1534248E/pt unknown
- 2003-06-30 BR BR0312563-7A patent/BR0312563A/pt not_active IP Right Cessation
- 2003-06-30 NZ NZ537278A patent/NZ537278A/en unknown
- 2003-06-30 OA OA1200500007A patent/OA12883A/en unknown
- 2003-06-30 MX MXPA05000394A patent/MXPA05000394A/es active IP Right Grant
- 2003-06-30 EP EP03764059A patent/EP1534248B1/en not_active Expired - Lifetime
- 2003-06-30 SI SI200332150T patent/SI1534248T1/sl unknown
- 2003-06-30 KR KR1020057000369A patent/KR100782693B1/ko not_active Expired - Fee Related
- 2003-06-30 AT AT03764059T patent/ATE550017T1/de active
- 2003-06-30 CA CA002489407A patent/CA2489407C/en not_active Expired - Fee Related
- 2003-07-01 US US10/612,679 patent/US20040057992A1/en not_active Abandoned
- 2003-07-04 TW TW092118389A patent/TW200406222A/zh unknown
- 2003-07-07 HN HN2003000206A patent/HN2003000206A/es unknown
- 2003-07-07 PE PE2003000682A patent/PE20040104A1/es not_active Application Discontinuation
- 2003-07-08 AR AR20030102454A patent/AR040434A1/es not_active Application Discontinuation
- 2003-07-08 UY UY27886A patent/UY27886A1/es not_active Application Discontinuation
2004
- 2004-12-13 IL IL165746A patent/IL165746A/en active IP Right Grant
- 2004-12-13 IS IS7594A patent/IS7594A/is unknown
- 2004-12-17 ZA ZA200410196A patent/ZA200410196B/en unknown
2005
- 2005-01-03 NO NO20050018A patent/NO20050018L/no not_active Application Discontinuation
- 2005-01-10 TN TNP2005000006A patent/TNSN05006A1/fr unknown
- 2005-01-10 MA MA28036A patent/MA27318A1/fr unknown
- 2005-01-10 EC EC2005005528A patent/ECSP055528A/es unknown
2006
- 2006-11-09 JP JP2006303440A patent/JP2007031451A/ja active Pending
- 2006-12-22 US US11/615,511 patent/US7553500B2/en not_active Expired - Fee Related
2012
- 2012-06-06 CY CY20121100504T patent/CY1112892T1/el unknown

Also Published As

Publication number	Publication date
CA2489407C (en)	2009-01-27
EA200401583A1 (ru)	2005-06-30
US7553500B2 (en)	2009-06-30
CN1668285A (zh)	2005-09-14
TNSN05006A1 (fr)	2007-05-14
AR040434A1 (es)	2005-04-06
NZ537278A (en)	2007-07-27
JP2005535671A (ja)	2005-11-24
ZA200410196B (en)	2006-07-26
MXPA05000394A (es)	2005-03-23
UY27886A1 (es)	2004-02-27
CA2489407A1 (en)	2004-01-22
EP1534248A1 (en)	2005-06-01
PL374913A1 (en)	2005-11-14
AU2003247017A1 (en)	2004-02-02
IS7594A (is)	2004-12-13
TW200406222A (en)	2004-05-01
KR20050017102A (ko)	2005-02-21
US20040057992A1 (en)	2004-03-25
IL165746A0 (en)	2006-01-15
PT1534248E (pt)	2012-05-25
PE20040104A1 (es)	2004-02-27
EP1534248B1 (en)	2012-03-21
EA007268B1 (ru)	2006-08-25
HN2003000206A (es)	2004-07-27
NO20050018L (no)	2005-01-12
BR0312563A (pt)	2005-04-19
CY1112892T1 (el)	2016-04-13
ECSP055528A (es)	2005-03-10
MA27318A1 (fr)	2005-05-02
AP2005003201A0 (en)	2005-03-31
SI1534248T1 (sl)	2012-07-31
ES2395123T3 (es)	2013-02-08
AU2003247017B2 (en)	2008-03-06
CN100344278C (zh)	2007-10-24
JP2007031451A (ja)	2007-02-08
DK1534248T3 (da)	2012-06-25
IL165746A (en)	2008-12-29
HRP20041196A2 (en)	2005-04-30
WO2004006895A1 (en)	2004-01-22
KR100782693B1 (ko)	2007-12-07
PA8576201A1 (es)	2004-05-26
JP4446446B2 (ja)	2010-04-07
US20070110800A1 (en)	2007-05-17
HK1077747A1 (en)	2006-02-24
ATE550017T1 (de)	2012-04-15

Publication	Publication Date	Title
US7553500B2 (en)	2009-06-30	Pharmaceutical composition having uniform drug distribution and potency
US7176221B2 (en)	2007-02-13	Low dose pharmaceutical composition having uniform drug distribution and potency
AU2002236166A1 (en)	2003-04-17	Method for manufacturing a low dose pharmaceutical composition
CN112472677A (zh)	2021-03-12	肾素那敏制剂及其制备方法
HK1077747B (en)	2008-02-22	Lasofoxifene tablet and its coating
HK1065705B (en)	2006-06-30	Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency